Blueberry Therapeutics are pleased to announce they have dosed the first patient in a Phase I/II clinical trial of BB2603 in fungal infection of the skin and nail following successful regulatory and ethics approvals. The [...]
David gave a presentation to Manchester Metropolitan University as part of their Biomedical Away Day. His presentation was on the Opportunities and Challenges in collaborating between Universities and Industry.
Mike Davies, CMO and Co-founder, presented at the SMI Conference “Adaptive Designs in Clinical Trials” in London on 4th April 2017. In it, Mike described how Blueberry Therapeutics utilises adaptive clinical trial designs for its lead [...]
Blueberry's CEO John Ridden was interviewed by Times writer Michael Cape. John and Michael spoke about how Blueberry benefitted from AstraZeneca's move to Cambridge, which led to husband and wife team David and Julie [...]
The Blueberry Clinical Team, consisting of Dr Mike Davies, co-founder and Chief Medical Officer, Mark Sidaway, Clinical Project Manager and Jane Davies, Senior CRA, held their site initiation visit (SIV) at the Parexel Early [...]